This paper argues that five conditions currently diagnosed and treated as separate disorders — cortisol-gated ADHD, seasonal affective disorder, occupational burnout, treatment-resistant depression, and the hypoarousal presentation of complex PTSD — may share a single upstream cause in a subset of patients: FKBP5 T-allele dynamics modulating glucocorticoid receptor sensitivity and glutamate receptor availability across multiple timescales.
Reframe the genotype. FKBP5 T/T is not a risk allele. It is a calibration system that amplifies environmental influence in both directions. The psychiatric literature's fixation on pathology has produced a sampling bias — nobody genotypes the thriving T-allele carriers in high-intensity careers because they never present clinically.
Recognize glutamate as the primary functional deficit. FKBP5 impairs glutamate through two independent pathways: reduced cortisol-driven glutamate release AND direct FKBP51-mediated AMPA receptor stripping. Glutamate is the excitatory signal required for dopamine, serotonin, and norepinephrine neurons to fire. Many conditions currently attributed to dopamine or serotonin deficits may be glutamate deficits in disguise — particularly in FKBP5 T-allele carriers, where the glutamate deficit is disproportionate to the cortisol deficit.
Rethink ADHD stimulant treatment in T-allele carriers. Stimulants compensate for the dopamine deficit but do not reverse the underlying glutamatergic abnormality (Maltezos et al., 2014). Lithium orotate, by restoring tonic glutamate through GSK3β inhibition, addresses a different layer of the problem and may be more effective than increased stimulant dose in T-allele carriers.
Treat circulating cortisol as one input, not the dependent variable. The inconsistent cortisol findings in the SAD, ADHD, burnout, and depression literature reflect a measurement-framework problem. Effective GR activation — not cortisol level — is what determines outcomes, and it depends on FKBP5 genotype, NR3C1 methylation state, AMPA receptor density, GSK3β activity, and photoperiod history alongside circulating cortisol. Two individuals with identical cortisol can be in functionally different states. Null results and contradictory findings in the cortisol literature should be read as evidence that the field has been measuring the wrong variable, not as evidence that stress hormones are unrelated to these conditions. Stratifying existing datasets by FKBP5 genotype and childhood adversity should resolve a substantial portion of the inconsistency.
Recognize the wired-but-tired triad as a single condition. Burnout patients presenting with simultaneous anxiety (wired — LC disinhibition), fatigue (tired — PNMT-mediated epinephrine deficit), and depression (flat — prefrontal/striatal GR desensitization and glutamate depletion) are not comorbid. They have one condition expressing through multiple downstream pathways.
Implement year-round photoperiod management for SAD. The coupled oscillation model predicts that summer light management is equally important as winter light therapy — reducing summer GR desensitization attenuates the autumn lag that produces winter depression.
Reconsider the treatment escalation ladder. The standard psychiatric response to worsening symptoms — a ladder of decreasing stimulation — may worsen T-allele patients by driving cortisol and glutamate further below their activation range.
Reassess children from adversity who appear cognitively impaired. State-dependent cognitive performance — offline in quiet classrooms, sharp under high engagement — is a predicted consequence of a permanently elevated activation threshold, not intellectual limitation.
1. Lithium orotate versus increased stimulant dose in ADHD stratified by FKBP5. Recruit adults with ADHD on stable stimulant doses reporting incomplete relief, stratified by genotype. Randomize to (a) increased stimulant dose, (b) addition of lithium orotate, or (c) lithium orotate alone with stimulant taper. Prediction: T-allele carriers show superior improvement with lithium because their deficit is glutamatergic — both insufficient release and accelerated AMPA receptor removal — not purely dopaminergic.
2. Genotype by occupation/environment fit. Is the T allele overrepresented in high-intensity, fast-feedback roles (emergency medicine, trading, startups) relative to equally demanding but calmer roles (accounting, library science, academic research)? Prediction: T-allele frequency will be significantly higher in high-stimulation roles, particularly among top performers.
3. Hippocampal preservation by genotype in trauma survivors. Using existing neuroimaging datasets (e.g., ENIGMA-PGC PTSD consortium), compare hippocampal volume in T-allele carriers versus CC carriers with matched trauma exposure, stratified by time since trauma. Prediction: T-allele carriers show relatively preserved hippocampal volume in the acute-to-subacute phase (months to a few years post-trauma) with the gap narrowing at longer time points, and equal or greater prefrontal/striatal changes throughout. This explains why T/T trauma survivors often present with hypoarousal/depression rather than classic PTSD acutely while still developing structural pathology on longer timescales.
4. Ketamine response by FKBP5 genotype. Retrospectively genotype participants from existing ketamine trials for rs1360780. Separate single-dose sustained responders from series-dependent responders. Prediction: single-dose responders enriched for T-allele carriers with adversity (GR desensitization patients), series-dependent responders distributed uniformly (circuit-damage patients).
5. Mifepristone for burnout. Randomize genotyped burnout patients to mifepristone (7 days) versus placebo. Prediction: T-allele carriers show significant functional improvement by day 28.
6. Lithium orotate as a light therapy amplifier. Randomize SAD patients to (a) light therapy alone, (b) lithium orotate alone, (c) combined, or (d) placebo. Prediction: combined group shows superior response because GSK3β inhibition restores glutamate in the visual cortex, amplifying the effective signal from the same light box.
7. NE:epinephrine ratio as a biomarker of GR desensitization. Measure catecholamines in burnout patients stratified by FKBP5 genotype. Prediction: T-allele carriers show elevated NE:epinephrine ratio reflecting impaired PNMT conversion. Ratio should normalize following recovery.
8. Summer light management for SAD. Randomize T-allele SAD patients to summer light management versus control. Prediction: managed group shows reduced winter severity despite no winter-specific intervention.
9. Treatment interaction by genotype. Compare standard care (stress reduction) versus activation-focused care (high-intensity activity, social density). Prediction: T-allele carriers respond better to activation, CC carriers respond better to standard care.
10. Lithium orotate and baseline cortisol. Recruit individuals with documented low morning cortisol, stratified by FKBP5 genotype. Administer lithium orotate for 8 weeks. Prediction: lithium-treated individuals show increases in cortisol awakening response through increased photic sensitivity, with the effect larger in T-allele carriers.
11. Baseline GSK3β activity by genotype and childhood adversity. Measure GSK3β phosphorylation at Ser9 (the inhibitory site) in peripheral blood mononuclear cells from T/T versus CC carriers, stratified by childhood adversity history, in the absence of active stress. This resolves the open question of whether the climate-layer FKBP51 direct inhibition of GSK3β (Gassen et al., 2015) compensates for the reduced GR→Akt→GSK3β arm, or whether net GSK3β activity is elevated at baseline in T/T carriers with childhood adversity. Prediction: T/T carriers with childhood adversity show modestly reduced Ser9 phosphorylation (more active GSK3β) relative to CC carriers, but less dramatically than T/T carriers measured during active burnout recovery.
12. Environmental activation versus lithium for climate-layer mismatch. The strongest version of the environment-matching argument predicts that lithium addresses GSK3β-mediated synaptic degradation but does not substitute for the breadth of GR signaling — leaving LC modulation, PNMT-driven epinephrine production, and PFC dopamine release unaddressed. Recruit T/T carriers with documented childhood adversity (Klengel-positive by intron 7 methylation or clinical proxy), stratified at baseline by environmental intensity (validated actigraphy plus self-reported weekly activation exposure). Within each stratum, randomize to lithium orotate versus placebo for 12 weeks. Primary endpoints span four GR-output domains: (a) LC modulation measured via prepulse inhibition, pupillometric response during cognitive load, and low-frequency heart rate variability; (b) PFC dopamine-dependent function measured via n-back performance, task-switching, and spatial working memory; (c) epinephrine-dependent exercise capacity measured via plasma epinephrine response to a standardized exercise challenge and time-to-exhaustion; (d) GSK3β-dependent function measured via motor learning tasks and standardized measures of synaptic plasticity, serving as a positive control for lithium's known mechanism. Predictions: lithium improves domain (d) in both environmental strata but produces minimal improvement in (a), (b), or (c) within the mismatched stratum; the matched stratum shows superior function across (a), (b), and (c) regardless of lithium assignment; the matched-plus-lithium arm shows the best composite profile because matched activation engages GR signaling across domains while lithium suppresses any residual GSK3β overactivity. A null result — lithium improves (a), (b), and (c) in the mismatched stratum — would falsify the claim that these domains require cortisol-driven GR signaling and would significantly strengthen the case for lithium as a standalone intervention.